📰 9 sources covering this story

UK approves its second weight-loss pill while EU access lags

First covered 3 days ago · latest take 1 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

UK approves its second weight-loss pill while EU access lags
UK approves its second weight-loss pill while EU access lags
A decision on whether Britain's National Health Service will cover the drug is expected in November.
Reuters
Reuters1 hrs ago
Eli Lilly's weight-loss pill secures first European nod in Britain
Eli Lilly's weight-loss pill secures first European nod in Britain  Reuters
BBC News
BBC News4 hrs ago
New weight loss pill approved for use in UK
Foundayo is made by Eli Lilly, the drug firm behind the Mounjaro jab.
GB News
GB News4 hrs ago
UK becomes first in Europe to approve new once-daily weight loss pill
UK becomes first in Europe to approve new once-daily weight loss pill  GB News
Sky News
Sky News6 hrs ago
UK is first European nation to approve weight loss pill
The UK has become the first European nation to approve a pill which helps with weight loss and treats diabetes.
New once-daily weight loss pill approved by the UK medicines regulator
The UK has become the first country in Europe to approve Orforglipron
LBC News
LBC News7 hrs ago
Britain first in Europe to approve new weight-loss pill: Daily tablet hailed as breakthrough for obesity and diabetes - lbc.co.uk
Britain first in Europe to approve new weight-loss pill: Daily tablet hailed as breakthrough for obesity and diabetes  lbc.co.uk
Daily Mail
Daily Mail7 hrs ago
Another weight-loss tablet approved for use in UK - patients on pill shed two stone of body weight
Orforglipron, a once-daily tablet produced by the same manufacturers as Mounjaro, has been given the green light by British health officials.
New Scientist
New Scientist🏁 first to report3 days ago
Postbiotic supplement boosts body’s own GLP-1 and weight loss
A small trial suggests a supplement containing dead bacteria could offer a cheaper alternative to weight-loss drugs such as semaglutide, but further evidence is needed